Mobile Site ›
Print Friendly View

Test ID: HYPOG    
Hypoglycemic Agent Screen, Serum

Secondary ID A test code used for billing and in test definitions created prior to November 2011

82439

NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Useful For Suggests clinical disorders or settings where the test may be helpful

Evaluation of suspected insulinoma characterized by hypoglycemia and increased plasma insulin concentration.

 

Detecting drugs that stimulate insulin secretion

 

If hypoglycemia is the result of 1 of these drugs, the test will detect the drug at physiologically significant concentrations in serum during an episode of hypoglycemia.

 

Drugs detected by this procedure are:

-The first-generation sulfonylureas-acetohexamide, chlorpropamide, tolazamide, and tolbutamide

-The second-generation sulfonylureas--glimepiride, glipizide, and glyburide

-The meglitinide-repaglinide

 

Drugs designed to make tissues more sensitive to insulin that do not induce hypoglycemia, such as pioglitazone, rosiglitazone, and troglitazone (recently withdrawn from the United States market) are not included in this screen test.

 

Drugs that lower blood glucose through mechanisms not related to stimulation of insulin secretion, such as acarbose, metformin, and miglitol are not included in this screen test.

Method Name A short description of the method used to perform the test

Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)

Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name

Hypoglycemic Agent Scrn, S

Aliases Lists additional common names for a test, as an aid in searching

Amaryl
Chlorpropamide
Dymelor
Glimepiride
Glipizide
Glucotrol
Glyburide
Meglitinides
Micronase
Prandin
Repaglinide
Sulfonylurea Hypoglycemic Serum
Sulfonylureas
Tolazamide (Tolinase)
Acetohexamide (Dymelor)
Orinase (Tolbutamide)
Diabinese (Chlorpropamide)